Compare eBay Inc (EBAY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Incyte Corporation — how do they compare? eBay Inc trades at $112.12 (market cap $49.83B), while Incyte Corporation trades at $112.8 (market cap $22.85B). The key difference: eBay Inc is far larger — about 2.2× Incyte Corporation's market cap, and eBay Inc pays a 1.11% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold eBay Inc for 134 Days and Incyte Corporation for 33 Days on average.
| EBAY | INCY | |
|---|---|---|
Market Cap | $49.83B | $22.85B |
Volume | 2,986,953 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $129.93 |
52-Week Low | $79.41 | $83.80 |
Typical Hold Time | 134 Days | 33 Days |
Enterprise Value | $53.65B | $18.35B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
eBay (EBAY) trades at $107.6, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $117.68 implying upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is steady, reaching $11.10B in 2025, supported by strong profitability margins including a net income margin of 18.57% and an impressive ROE of 47.38%.
The outlook is positive, driven by earnings momentum and strategic focus on collectibles and live commerce, but risks include competitive pressures from Amazon's new multi-platform tools and potential volatility from GameStop's significant stake. Investor sentiment is mixed, with nearly equal buy and hold ratings from analysts.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
